Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)	Feb. 12, 2021 USD ($)	Dec. 31, 2021
Cost of Borrowing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Counterparty cost of borrowing		0.127
SFJ Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Committed funding	$ 150,000,000
Success-based payments, first indication	$ 450,000,000
Success-based payments, first indication, period to be paid	5 years
Success-based payments, first payment	$ 30,000,000
Success-based payments, second indication	$ 150,000,000
Success-based payments, second indication, period to be paid	7 years
Additional indication payment	$ 37,500,000
SFJ Pharmaceuticals | Cost of Borrowing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Counterparty cost of borrowing		0.015